| Literature DB >> 30029595 |
Wei Shi1, Denian Wen2, Changhui Chen3, Lin Yuan1, Wei Gao1, Ping Tang2, Xiaoping Cheng3, Kaihu Yao4.
Abstract
BACKGROUND: Moraxella catarrhalis (M. catarrhalis) is an important bacterial pathogen. However, its antibiotic susceptibility patterns in different areas are difficult to compare because of the use of different methods and judgement criteria. This study aimed to determine antimicrobial susceptibility and β-lactamase activity characteristics of M. catarrhalis isolates collected from two county hospitals in China, and to express the results with reference to three commonly used judgement criteria.Entities:
Keywords: Antibiotic resistance; Children; Moraxella catarrhalis; β-Lactamase
Mesh:
Substances:
Year: 2018 PMID: 30029595 PMCID: PMC6054730 DOI: 10.1186/s12866-018-1217-5
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Antibiotic breakpoints for M. catarrhalis strains in EUCAST, CLSI and BSAC
| Antibiotics* | MICa/D-zoneb | EUCASTc | CLSId | BSACe | |||||
|---|---|---|---|---|---|---|---|---|---|
| S | R | S | I | R | S | I | R | ||
| AMP | MIC(mg/L) | -# | -# | -# | -# | -# | ≤1 | – | > 1 |
| AMC | MIC(mg/L) | ≤1 | >1 | ≤4 | – | ≥8 | ≤1 | – | > 1 |
| CXM | MIC(mg/L) | ≤4 | >8 | ≤4 | 8 | ≥16 | ≤1 | 2 | > 2 |
| CAZ | MIC(mg/L) | -# | -# | ≤2 | -# | -# | -# | -# | -# |
| FEP | MIC(mg/L) | ≤4 | >4 | -# | -# | -# | -# | -# | -# |
| CIP | MIC(mg/L) | ≤0.5 | >0.5 | ≤1 | -# | -# | ≤0.5 | – | > 0.5 |
| ERY | MIC(mg/L) | ≤0.25 | >0.5 | ≤0.5 | 1–4 | ≥8 | ≤0.25 | 0.5 | > 0.5 |
| MEM | MIC(mg/L) | ≤2 | >2 | -# | -# | -# | -# | -# | -# |
| TCY | D-zone(mm) | ≥28 | <25 | ≥29 | 25–28 | ≤24 | ≥22 | – | ≤21 |
| CHL | D-zone(mm) | ≥30 | <30 | -# | -# | -# | -# | -# | -# |
| SXT | D-zone(mm) | ≥18 | <15 | ≥13 | 11–12 | ≤10 | ≥12 | – | ≤11 |
aMIC minimum inhibitory concentration, bD-zone diameter of inhibition zone, cEUCAST, European Committee on Antimicrobial Susceptibility Testing, dCLSI Clinical and Laboratory Standards Institute, eBSAC British Society for Antimicrobial Chemotherapy, *AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, # no breakpoints listed in the according criterion
Susceptibility of the Moraxella catarrhalis isolates in Youyang, Zhongjiang and total profiles according to EUCAST, CLSI and BSAC
| Antibiotics* | Youyang | Zhongjiang | Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I% | R% | MIC50 | MIC90 | MIC Range | I% | R% | MIC50 | MIC90 | MIC Range | I% | R% | MIC50 | MIC90 | MIC Range | ||
| EUCASTa | AMP | – | – | 2 | 4 | 0.016~ 16 | – | – | 2 | 6 | 0.032~ 12 | – | – | 2 | 6 | 0.032–12 |
| AMC | – | 0 | 0.19 | 0.38 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016–0.38 | |
| CXM | 8.9 | 0 | 2 | 4 | 0.023~ 8 | 18.2 | 1.3 | 3 | 6 | 0.047~ 16 | 12.9 | 0.6 | 3 | 6 | 0.047–16 | |
| CAZ | – | – | 0.125 | 0.38 | 0.023~ 2 | – | – | 0.094 | 0.38 | 0.032~ 1 | – | – | 0.094 | 0.38 | 0.032–1 | |
| FEP | – | 4.0 | 1.5 | 4 | 0.064~ 6 | – | 1.3 | 1.5 | 4 | 0.19~ 6 | – | 2.8 | 1.5 | 4 | 0.19–6 | |
| CIP | – | 2.0 | 0.047 | 0.19 | 0.016~ 1 | – | 5.2 | 0.047 | 0.094 | 0.016~ 1 | – | 3.4 | 0.047 | 0.094 | 0.016–1 | |
| ERY | 28.7 | 64.4 | 0.75 | > 256 | 0.047~ > 256 | 11.7 | 79.2 | 2 | > 256 | 0.19~ > 256 | 21.3 | 70.8 | 2 | 256 | 0.19- > 256 | |
| MEM | – | 0 | 0.006 | 0.008 | 0.003~ 0.38 | – | 0 | 0.006 | 0.008 | 0.003~ 0.023 | – | 0 | 0.006 | 0.008 | 0.003–0.38 | |
| TCY | 3.0 | 5.9 | 0 | 3.9 | 1.7 | 5.1 | ||||||||||
| CHL | – | 4.0 | – | 3.9 | – | 3.9 | ||||||||||
| SXT | 9.9 | 30.7 | 7.8 | 3.9 | 9.0 | 19.1 | ||||||||||
| CLSIb | AMC | – | 0 | 0.19 | 0.38 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016–0.38 |
| CXM | 8.9 | 0 | 2 | 4 | 0.023~ 8 | 18.2 | 1.3 | 3 | 6 | 0.047~ 16 | 12.9 | 0.6 | 3 | 6 | 0.047–16 | |
| CAZ | -# | -# | 0.125 | 0.38 | 0.023~ 2 | -# | -# | 0.094 | 0.38 | 0.032~ 1 | -# | -# | 0.094 | 0.38 | 0.032–1 | |
| CIP | -# | -# | 0.047 | 0.19 | 0.016~ 1 | -# | -# | 0.047 | 0.094 | 0.016~ 1 | -# | -# | 0.047 | 0.094 | 0.016–1 | |
| ERY | 48.5 | 15.8 | 0.75 | > 256 | 0.047~ > 256 | 44.1 | 35.1 | 2 | > 256 | 0.19~ > 256 | 47.8 | 23.0 | 2 | > 256 | 0.19- > 256 | |
| TCY | 20.8 | 5.9 | 3.9 | 3.9 | 13.5 | 5.1 | ||||||||||
| SXT | 6.9 | 16.8 | 0 | 1.3 | 3.9 | 10.1 | ||||||||||
| BSACc | AMP | – | 68.3 | 2 | 4 | 0.016~ 16 | – | 81.8 | 2 | 6 | 0.032~ 12 | – | 74.2 | 2 | 6 | 0.032–12 |
| CXM | 45.5 | 49.5 | 2 | 4 | 0.023~ 8 | 44.2 | 53.2 | 3 | 6 | 0.047~ 16 | 44.9 | 51.1 | 3 | 6 | 0.047–16 | |
| TCY | – | 5.9 | – | 3.9 | – | 5.1 | ||||||||||
| SXT | – | 19.8 | – | 1.3 | – | 11.8 | ||||||||||
aEUCAST European Committee on Antimicrobial Susceptibility Testing, bCLSI Clinical and Laboratory Standards Institute, cBSAC British Society for Antimicrobial Chemotherapy, *AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, # no breakpoints were listed in the according criterion, but the other “-“s mean no data